Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Get Free Report)'s stock price was down 3.5% on Friday . The stock traded as low as $8.61 and last traded at $8.66. Approximately 163,920 shares changed hands during mid-day trading, a decline of 82% from the average daily volume of 911,880 shares. The stock had previously closed at $8.97.
Analyst Ratings Changes
PHAT has been the subject of several recent analyst reports. HC Wainwright restated a "buy" rating and issued a $28.00 target price on shares of Phathom Pharmaceuticals in a research report on Monday, August 12th. The Goldman Sachs Group raised their target price on Phathom Pharmaceuticals from $10.00 to $12.00 and gave the company a "neutral" rating in a research report on Friday, August 9th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $26.00 price target on shares of Phathom Pharmaceuticals in a research report on Friday, September 13th.
Get Our Latest Report on PHAT
Phathom Pharmaceuticals Price Performance
The firm has a market capitalization of $606.53 million, a P/E ratio of -1.56 and a beta of 0.72. The firm's fifty day moving average price is $14.68 and its 200-day moving average price is $13.29.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of PHAT. Eagle Asset Management Inc. boosted its position in shares of Phathom Pharmaceuticals by 25.9% during the 3rd quarter. Eagle Asset Management Inc. now owns 455,196 shares of the company's stock valued at $7,675,000 after purchasing an additional 93,733 shares in the last quarter. Oracle Investment Management Inc. bought a new position in shares of Phathom Pharmaceuticals in the second quarter valued at $2,318,000. Vanguard Group Inc. lifted its position in shares of Phathom Pharmaceuticals by 1.2% during the 1st quarter. Vanguard Group Inc. now owns 1,979,113 shares of the company's stock valued at $21,018,000 after acquiring an additional 22,684 shares during the last quarter. Jennison Associates LLC lifted its position in shares of Phathom Pharmaceuticals by 112.7% during the 3rd quarter. Jennison Associates LLC now owns 5,866,389 shares of the company's stock valued at $106,064,000 after acquiring an additional 3,108,810 shares during the last quarter. Finally, Marshall Wace LLP bought a new stake in shares of Phathom Pharmaceuticals during the 2nd quarter worth $1,161,000. Institutional investors own 99.01% of the company's stock.
Phathom Pharmaceuticals Company Profile
(
Get Free Report)
Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.
See Also
Before you consider Phathom Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phathom Pharmaceuticals wasn't on the list.
While Phathom Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
